home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Pier Shareware 6
/
The_Pier_Shareware_Number_6_(The_Pier_Exchange)_(1995).iso
/
026
/
med9410a.zip
/
M94A0118.TXT
< prev
next >
Wrap
Text File
|
1994-10-01
|
3KB
|
45 lines
Document 0118
DOCN M94A0118
TI Etoposide: current status and future perspectives in the management of
malignant neoplasms.
DT 9412
AU Belani CP; Doyle LA; Aisner J; University of Pittsburgh Medical Center,
Pittsburgh Cancer; Institute, Division of Medical Oncology 15213.
SO Cancer Chemother Pharmacol. 1994;34 Suppl:S118-26. Unique Identifier :
AIDSLINE MED/94349496
AB Etoposide has demonstrated highly significant clinical activity against
a wide variety of neoplasms, including germ-cell malignancies,
small-cell lung cancer, non-Hodgkin's lymphomas, leukemias, Kaposi's
sarcoma, neuroblastoma, and soft-tissue sarcomas. It is also one of the
important agents in the preparatory regimens given prior to bone marrow
and peripheral stem-cell rescue. Despite its high degree of efficacy in
a number of malignancies, the optimal dose, schedule, and dosing form
remain to be defined. It is possible that continuous or prolonged
inhibition of the substrate, i. e., topoisomerase II, may be the key
factor for the cytotoxic effects of etoposide. Clinical studies have
shown the activity of etoposide to be schedule-dependent, with prolonged
dosing, best accomplished by the oral dosing form, offering a
therapeutic advantage. This benefit awaits validation by prospective
randomized studies, some of which are in progress. Recent clinical
investigations have focused on the use of etoposide in combination with
(a) cytokines to ameliorate myelosuppression, the dose-limiting toxicity
of etoposide; (b) agents such as cyclosporin A and verapamil to alter
the p-glycoprotein (mdr1) function; and (c) topoisomerase I inhibitors
to modulate the substrate upon which it acts. There is continued
interest in the development of etoposide to its maximal clinical
dimensions and in the examination of alternative biochemical and
mechanistic approaches to further our understanding of this highly
active agent.
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS Antineoplastic Agents,
Combined/*THERAPEUTIC USE Carcinoma, Non-Small-Cell Lung/DRUG THERAPY
Carcinoma, Small Cell/DRUG THERAPY Etoposide/ADMINISTRATION &
DOSAGE/*THERAPEUTIC USE Germinoma/DRUG THERAPY Human Leukemia,
Myelocytic, Acute/DRUG THERAPY Lung Neoplasms/*DRUG THERAPY
Lymphoma/DRUG THERAPY Neoplasms/*DRUG THERAPY Sarcoma, Kaposi's/DRUG
THERAPY/ETIOLOGY Stomach Neoplasms/DRUG THERAPY JOURNAL ARTICLE
REVIEW REVIEW, ACADEMIC
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).